ADAMTS9 and cancer: However, its role may vary depending on the cancer type as downregulation of ADAMTS9-AS2 in breast cancer was reported to increase tamoxifen resistance, whereas its downregulation was associated with increased sensitivity to temozolomide in glioblastoma [71,72].